＊No.352026/4/19 22:48報告>>34Authorized shares (300M) are nearly exhausted, limiting capital flexibility. Pre–major milestone dilution is a common strategic move in cash-strapped biotech.返信投資の参考になりましたか？はい10いいえ1
